A $1.3 million grant from the National Cancer Institute will allow a University of Utah lab and a Salt Lake City startup company to create software to help doctors tailor cancer treatments to individual patients in the future.
Dan Kadrmas, Ph.D., professor of radiology, has developed technologies in his lab to use PET (positron emission tomography) imaging to look at multiple aspects of tumor function simultaneously such as blood flow and growth rate. The goal is to use that technology to predict which drug therapies will work best in individual patients. “Where we’ve been for the last 20 years is we’ve had drugs that were broadly used for groups of patients,” Kadrmas said in a statement. “Now we’re trying to do personalized medicine.”
The technology is specifically designed for targeted cancer therapies, which work well in a small percentage of patients. The new imaging software will be used to guide targeted therapies and improve results for patients with a variety of cancers including breast, lung, pancreatic and brain tumors.
The four-year grant—which is a renewal of a previous one from NCI—will allow Kadrmas and the company he founded, MultiFunctional Imaging, to create software that can be used in clinical trials to generate data showing which treatment is more effective. It may take about four years to get the software to those trials, and after several years of research, the software should then be available on a widespread basis. “That’s what’s exciting for me,” Kadrmas said. “We do a lot of research that never reaches the patient. Now through this partnership we have a nice mechanism to deliver the technology to the patient."
Get the latest information on Health IT and attend other valuable sessions at this two-day Summit providing healthcare leaders with educational content, insightful debate and dialogue on the future of healthcare and technology.